Latest news with #XENE
Yahoo
03-07-2025
- Business
- Yahoo
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and increased its price target from $55 to $57 on June 13. The change comes after the company examined the translatability of previous Phase II to Phase III medications for epilepsy. The bank's study showed a strong association between the efficacy results of Phase II and Phase III drugs for focal onset seizures, particularly in terms of responder rates and seizure reductions. According to the findings, Xenon's top medication candidate, azetukalner, will likely exhibit similarly encouraging outcomes in its Phase III data, which is expected to be released early next year. Azetukalner's novel Kv7 mechanism of action, quick onset, and possible mood improvements are cited by RBC Capital as competitive advantages in a market dominated by polypharmacy, with the firm suggesting that future sales might reach $1.2 billion. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a biopharmaceutical company that specializes in creating therapies for mental and neurological conditions, such as major depressive disorder (MDD) and epilepsy. While we acknowledge the potential of XENE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
28-06-2025
- Business
- Business Insider
Xenon Pharmaceuticals joins Russell 3000, Russell 2000 Indexes
Xenon Pharmaceuticals (XENE) announced that the company has been added to the broad-market Russell 3000 and small-cap Russell 2000 Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025. The Russell 3000 Index is an equity index that tracks the performance of the largest 3,000 U.S. stocks by market capitalization. The Russell 2000 Index measures the performance of the 2,000 smallest companies within the Russell 3000 Index. Inclusion in the Russell 2000 results in automatic inclusion in the appropriate growth and value style indexes. Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for investment strategies. Approximately $10.6T in assets are benchmarked against Russell U.S. indexes.
Yahoo
14-05-2025
- Business
- Yahoo
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats studying a biopharmaceutical molecule in a lab. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) decreased by 17.43 percent on Tuesday to finish at $29.60 apiece following the delayed results of its Phase 3 epilepsy study and a dismal earnings performance in the first quarter of the year. In a statement, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that the results of the study are now expected to be released in early 2026. 'While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study, which represents a significant milestone for Xenon, getting us one step closer to a potential first commercial product launch,' said President and CEO Ian Mortimer. In the first three months of the year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said net loss widened by 35.7 percent to $65 million from $47.9 million in the same period last year, despite incurring $7.5 million in revenues during the period. Research and development expenses grew by 38 percent to $61.2 million from $44.3 million year-on-year. Overall XENE ranks 3rd on our list of Tuesday's worst performers. While we acknowledge the potential of XENE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XENE but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats studying a biopharmaceutical molecule in a lab. Xenon Pharmaceuticals Inc. (NASDAQ:XENE) decreased by 17.43 percent on Tuesday to finish at $29.60 apiece following the delayed results of its Phase 3 epilepsy study and a dismal earnings performance in the first quarter of the year. In a statement, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said that the results of the study are now expected to be released in early 2026. 'While this timing represents a modest shift from our prior guidance, we are encouraged that we are nearing the end of this important study, which represents a significant milestone for Xenon, getting us one step closer to a potential first commercial product launch,' said President and CEO Ian Mortimer. In the first three months of the year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) said net loss widened by 35.7 percent to $65 million from $47.9 million in the same period last year, despite incurring $7.5 million in revenues during the period. Research and development expenses grew by 38 percent to $61.2 million from $44.3 million year-on-year. Overall XENE ranks 3rd on our list of Tuesday's worst performers. While we acknowledge the potential of XENE as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XENE but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.


Washington Post
27-02-2025
- Business
- Washington Post
Xenon Pharmaceuticals: Q4 Earnings Snapshot
BURNABY, British Columbia — BURNABY, British Columbia — Xenon Pharmaceuticals Inc. (XENE) on Thursday reported a loss of $65.7 million in its fourth quarter. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 84 cents. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share.